Inulin Gut Microbiome Randomized Trial Evidence Table

Structured evidence table for Inulin Gut Microbiome Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.

topicclaimevidence levelcitationsource
Inulin Gut Microbiome Randomized TrialProtocol of the LEONORA randomized clinical trial: Lower gastrointestinal symptom burden by prophylaxis with synbiotics after colorectal cancer surgery.2Schöttker B (2026)Protocol of the LEONORA randomized clinical trial: Lower gastrointestinal symptom burden by prophylaxis with synbiotics after colorectal cancer surgery.
Inulin Gut Microbiome Randomized TrialIn addition to its high prevalence and disability burden, migraine is associated with substantial socioeconomic costs, with estimated direct and indirect expenditures of approximately USD 36 billion annually in the United States [].3Kozák Márk (2026)Migraine and the Gut–Brain Axis—The Role of Microbiome-Targeted Biotics
Inulin Gut Microbiome Randomized TrialClinically, migraine is characterized by recurrent attacks of moderate-to-severe headache lasting 4–72 h, typically unilateral and pulsating, aggravated by routine physical activity, and frequently accompanied by photophobia and phonophobia; in a substantial subset of patients, attacks are associated with reversible focal neurological symptoms called aura.3Kozák Márk (2026)Migraine and the Gut–Brain Axis—The Role of Microbiome-Targeted Biotics
Inulin Gut Microbiome Randomized Trial6 7 8 9 10 11 12 2 13 14 10 15 16 Helicobacter pylori The most common gastrointestinal disorders associated with migraine are irritable bowel syndrome (IBS) (reported in up to 50% of patients with migraine []), inflammatory bowel disease (IBD) [,,], gastroesophageal reflux disease (GERD) [], functional dyspepsia [,], cyclic vomiting syndrome [], peptic ulcers andinfections [,].3Kozák Márk (2026)Migraine and the Gut–Brain Axis—The Role of Microbiome-Targeted Biotics
Inulin Gut Microbiome Randomized Trial1 2 3 4 2 3 5 Migraine is a prevalent primary headache disorder with significant morbidity and rising prevalence, affecting around 14% of the global population [].3Kozák Márk (2026)Migraine and the Gut–Brain Axis—The Role of Microbiome-Targeted Biotics

Source documents

  1. Protocol of the LEONORA randomized clinical trial: Lower gastrointestinal symptom burden by prophylaxis with synbiotics after colorectal cancer surgery.
  2. Migraine and the Gut–Brain Axis—The Role of Microbiome-Targeted Biotics